{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Xenon Pharmaceuticals, Inc.
Xenon Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout
Xenon Pharmaceuticals, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Despite a challenging year-to-date performance, bullish signals from daily moving averages, MACD, and On-Balance Volume suggest growing investor interest, prompting stakeholders to watch for potential improvements in the company's performance.
Is Xenon Pharmaceuticals, Inc. technically bullish or bearish?
As of September 9, 2025, Xenon Pharmaceuticals, Inc. shows a neutral technical stance with mixed indicators, transitioning from mildly bearish to sideways, while underperforming against the S&P 500 in the short term but significantly outperforming over the past five years.
Is Xenon Pharmaceuticals, Inc. overvalued or undervalued?
As of May 12, 2025, Xenon Pharmaceuticals is considered a risky investment due to its high Price to Book Value of 3.45, negative EV to EBITDA of -6.47, and poor ROE of -35.72%, alongside underperforming the S&P 500 with a return of -5.81% compared to the index's 17.14%.
Is Xenon Pharmaceuticals, Inc. technically bullish or bearish?
As of June 27, 2025, the market trend is mildly bearish, supported by bearish MACD readings and moving averages, despite some mild bullish signals from KST and OBV.
Is Xenon Pharmaceuticals, Inc. overvalued or undervalued?
As of May 12, 2025, Xenon Pharmaceuticals is considered risky and overvalued due to a Price to Book Value of 3.45, a negative EV to EBITDA of -6.47, and a troubling ROCE of -188.17%, especially when compared to peers like Corcept Therapeutics and Madrigal Pharmaceuticals, and it has underperformed the S&P 500 by 19.67% year-to-date.
Is Xenon Pharmaceuticals, Inc. technically bullish or bearish?
As of May 13, 2025, Xenon Pharmaceuticals, Inc. is in a bearish trend with moderate strength, indicated by bearish MACD readings, moving averages, and Bollinger Bands, despite a mildly bullish KST signal.
Who are in the management team of Xenon Pharmaceuticals, Inc.?
As of March 2022, the management team of Xenon Pharmaceuticals, Inc. includes Mr. Michael Tarnow (Independent Chairman), Dr. Simon Pimstone (Executive Chairman), Mr. Patrick Machado, Dr. Mohammad Azab, Dr. Clarissa Desjardins, and Mr. Steven Gannon (all Independent Directors). They oversee the company's strategic direction and operations.
What does Xenon Pharmaceuticals, Inc. do?
Xenon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Canada, focused on developing therapeutics for orphan diseases. As of March 2025, it reported net sales of $8 million and a net loss of $65 million, with a market cap of approximately $2.43 billion.
How big is Xenon Pharmaceuticals, Inc.?
As of Jun 18, Xenon Pharmaceuticals, Inc. has a market capitalization of $2.43 billion, with net sales of $7.50 million and a net profit of -$251.45 million over the last four quarters. The company's shareholder's funds are $754.90 million, and total assets amount to $1.07 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
